Highlights and Quick Summary
- Ending Cash for the quarter ending March 31, 2022 was $605 Million (a -2127.12% decrease compared to previous quarter)
- Year-over-year quarterly Ending Cash decreased by -2448.49%
- Annual Ending Cash for 2021 was $587 Million (a -9.53% decrease from previous year)
- Annual Ending Cash for 2020 was $649 Million (a 48.4% increase from previous year)
- Annual Ending Cash for 2019 was $437 Million (a -11.44% decrease from previous year)
- Twelve month Ending Cash ending March 31, 2022 was $525 Million (a -10.54% decrease compared to previous quarter)
- Twelve month trailing Ending Cash increased by 11.36% year-over-year
Trailing Ending Cash for the last four month:
|31 Mar '22||31 Dec '21||30 Sep '21||30 Jun '21|
|$525 Million||$587 Million||$251 Million||$472 Million|
Visit stockrow.com/BMRN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Ending Cash of BioMarin Pharmaceutical Inc.Most recent Ending Cashof BMRN including historical data for past 10 years.
Interactive Chart of Ending Cash of BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.